This discovery, published in Nature, could greatly improve the fight against antibiotic-resistant superbugs. Structure of a proteasome molecule. The proteasome is present in all cells of the body. Its ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

The proteasome, a huge complex of protein-cleaving ... the scientists found that the small-molecule fraction (of a mass of less than 10 kilodaltons) secreted into the extracellular environment ...

Oncology Small Molecule Drugs Market Expected to Grow Significantly Due to Industry Advancements. Growing Demand for Personalized Medicine and Target ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

With PROTACs, we are using a small molecule drug to harness that natural ... is tagged with ubiquitin to be degraded by the proteasome. Why would a PROTAC be better than traditional drugs?

To prevent this, cells have developed a sophisticated system to mark unwanted proteins for degradation with a small protein called ubiquitin. Ubiquitin chains Ubiquitin is a cellular tag that marks ...

It develops the Degronimid platform that incorporates small molecule binders to target disease ... the cell through the natural ubiquitin and proteasome system. The company was founded by James ...

Scientists at deCODE genetics, a subsidiary of Amgen,�reveal today in Nature Genetics associations between rare loss-of-function variants in two genes and bipolar disorder. Significant progress has ...

Targeted protein degraders are characterized by their bifunctional nature, binding to both a target protein and a ligase to drive ubiquitination and catalytic degradation of the target through the ...